Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)

Abstract : Although antiretroviral treatment decreases HIV-AIDS morbidity/mortality, long-term side effects may include the onset of insulin resistance and cardiovascular diseases. However, the underlying molecular mechanisms responsible for highly active antiretroviral therapy (HAART)-induced cardio-metabolic effects are poorly understood. In light of this, we hypothesized that HIV protease inhibitor (PI) treatment (Lopinavir/Ritonavir) elevates myocardial oxidative stress and concomitantly inhibits the ubiquitin proteasome system (UPS), thereby attenuating cardiac function. Lopinavir/Ritonavir was dissolved in 1% ethanol (vehicle) and injected into mini-osmotic pumps that were surgically implanted into Wistar rats for 8 weeks vs. vehicle and sham controls. We subsequently evaluated metabolic parameters, gene/protein markers and heart function (ex vivo Langendorff perfusions). PI-treated rats exhibited increased serum LDL-cholesterol, higher tissue triglycerides (heart, liver), but no evidence of insulin resistance. In parallel, there was upregulation of hepatic gene expression, i.e. acetyl-CoA carboxylase β and 3-hydroxy-3-methylglutaryl-CoA-reductase, key regulators of fatty acid oxidation and cholesterol synthesis, respectively. PI-treated hearts displayed impaired cardiac contractile function together with attenuated UPS activity. However, there was no significant remodeling of hearts exposed to PIs, i.e. lack of ultrastructural changes, fibrosis, cardiac hypertrophic response, and oxidative stress. Western blot analysis of PI-treated hearts revealed that perturbed calcium handling may contribute to the PI-mediated contractile dysfunction. Here chronic PI administration led to elevated myocardial calcineurin, nuclear factor of activated T-cells 3 (NFAT3), connexin 43, and phosphorylated phospholamban, together with decreased calmodulin expression levels. This study demonstrates that early changes triggered by PI treatment include increased serum LDL-cholesterol levels together with attenuated cardiac function. Furthermore, PI exposure inhibits the myocardial UPS and leads to elevated calcineurin and connexin 43 expression that may be associated with the future onset of cardiac contractile dysfunction.
Type de document :
Article dans une revue
PLoS ONE, Public Library of Science, 2013, 8 (9), pp.e73347. 〈10.1371/journal.pone.0073347〉
Liste complète des métadonnées

http://hal.univ-reunion.fr/hal-01198326
Contributeur : Nicolas Alarcon <>
Soumis le : vendredi 11 septembre 2015 - 21:06:03
Dernière modification le : vendredi 14 septembre 2018 - 08:17:05

Lien texte intégral

Identifiants

Collections

Citation

Kathleen M. S. E. Reyskens, Tarryn-Lee Fisher, Jonathan C. Schisler, Wendi G. O'Connor, Arlin B. Rogers, et al.. Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir). PLoS ONE, Public Library of Science, 2013, 8 (9), pp.e73347. 〈10.1371/journal.pone.0073347〉. 〈hal-01198326〉

Partager

Métriques

Consultations de la notice

243